Outpatient treatment options to address the SARS-CoV-2 variant Omicron

References

• Hozayen SM, Zychowski D, Benson S, et al. Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine. 2021;41:101139.
   PubMedGoogle Scholar
• Mornese Pinna S, Lupia T, Scabini S, et al. Monoclonal antibodies for the treatment of COVID-19 patients: an umbrella to overcome the storm? Int Immunopharmacol. 2021;101(Pt A):108200.
   PubMedGoogle Scholar
• Aschenbrenner DS. Another monoclonal antibody granted EUA to treat COVID-19. Am J Nurs. 2021;121(8):22.
   Google Scholar
• Abu-Melha S, Edrees MM, Said MA, et al. Potential COVID-19 drug candidates based on Diazinyl-Thiazol-Imine moieties: synthesis and greener pastures biological study. Molecules. 2022;27(2):488.
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients. Med Sci Monit. 2022;28:e935952.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al., Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21): 1941–1950.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2021;39:778–791 .
   Google Scholar
• Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2021;602:664–670.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021;602:657–663.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, et al. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022;16(2):102396.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021;602:654–656.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang P, Matsuoka Y, et al. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants. medRxiv. 2022. DOI:https://doi.org/10.1101/2022.01.12.22269023.
   Google Scholar
• Chen J, Wang R, Gilby NB, et al. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–422.
   PubMed Web of Science ®Google Scholar
• Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 2021;116:38–42.
   PubMed Web of Science ®Google Scholar
• Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism shift. Res Sq. 2022;19:413–422.
   Google Scholar
• Hageman JR, Alcocer AL. Omicron: a variant of concern? Pediatr Ann. 2022;51(1):e1.
   PubMedGoogle Scholar
• VanBlargan L, Errico J, Halfmann P, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Res Sq. 2021;82;3130–3139 .
   Google Scholar
• Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012–8018.
   PubMedGoogle Scholar
• Mohapatra RK, Sarangi AK, Kandi V, et al. Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario. J Med Virol. 2021;14:331–341.
   Google Scholar
• Fenwick C, Turelli P, Perez L, et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 2021;37:109814.
   PubMedGoogle Scholar
• Klein EJ, Hardesty A, Vieira K, et al. Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: efficacy, ethnic and racial disparities. Am J Transplant. 2021;22:640–645.
   PubMedGoogle Scholar
• Patrucco F, Gavelli F, Fagoonee S, et al. Current treatment challenges in the COVID-19 pandemic. Pol Arch Intern Med. 2021;131(9):854–861.
   PubMedGoogle Scholar
• Su W, Sia SF, Schmitz AJ, et al. Neutralizing monoclonal antibodies that target the spike receptor binding domain confer Fc receptor-independent protection against SARS-CoV-2 infection in syrian hamsters. mBio. 2021;12:e0239521.
   PubMedGoogle Scholar
• Ouranidis A, Choli-Papadopoulou T, Papachristou ET, et al. Biopharmaceutics 4.0, advanced pre-clinical development of mRNA-encoded monoclonal antibodies to immunosuppressed murine models. Vaccines (Basel). 2021;9(8). DOI:https://doi.org/10.3390/vaccines9080890
   Google Scholar
• Di D, Dileepan M, Ahmed S, et al. Recombinant SARS-CoV-2 nucleocapsid protein: expression, purification, and its biochemical characterization and utility in serological assay development to assess immunological responses to SARS-CoV-2 infection. Pathogens. 2021;10(8):1039.
   PubMedGoogle Scholar
• Hammarström L, Marcotte H, Piralla A, et al. Antibody therapy for COVID-19. Curr Opin Allergy Clin Immunol. 2021;21:553–558.
   PubMedGoogle Scholar
• Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
   PubMedGoogle Scholar
• Bartoletti M, Azap O, Barac A, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28(2):222–238.
   PubMed Web of Science ®Google Scholar
• Kumar RN, Wu EL, Stosor V, et al. Real-world experience of bamlanivimab for coronavirus disease 2019 (COVID-19): a case-control study. Clin Infect Dis. 2022;74(1):24–31.
   PubMedGoogle Scholar
• Group A-TfIwC-TS. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2021;24:991–997.
   Google Scholar
• Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021;374:n2231.
   PubMedGoogle Scholar
• Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021; 9: CD013825. https://doi.org/10.1002/14651858.CD013825.pub2.
   Google Scholar
• McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;32:543–550.
   Google Scholar
• Suran M. Federal government buys thousands of bebtelovimab doses. JAMA. 2022;327(12):1117.
   Google Scholar
• Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87–91.
   PubMedGoogle Scholar
• Deeks ED. Casirivimab/Imdevimab: first Approval. Drugs. 2021;81(17):2047–2055.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Syed AM, Ciling A, Khalid MM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv. 2022;63:3361–3369.
   Google Scholar
• Vitiello A, Troiano V, La Porta R. What will be the role of molnupiravir in the treatment of COVID-19 infection? Drugs Ther Perspect. 2021;29:776–781.
   Google Scholar
• Singh AK, Singh A, Singh R, et al. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.
   PubMed Web of Science ®Google Scholar
• Whitley R. Molnupiravir - A step toward orally bioavailable therapies for covid-19. N Engl J Med. 2021;31:1191–1198.
   Google Scholar
• Jayk Bernal A, da Silva Mm G, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2021;386:509–520.
   PubMed Web of Science ®Google Scholar
• García-Lledó A, Gómez-Pavón J, González Del Castillo J, et al. Pharmacological treatment of COVID-19: an opinion paper. Rev Esp Quimioter. 2021.
   Google Scholar
• Soriano V, de-Mendoza C, Edagwa B, et al. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Rev. 2022. DOI:https://doi.org/10.24875/AIDSRev.22000001.
   Google Scholar
• Waters MD, Warren S, Hughes C, et al. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environ Mol Mutagen. 2022;63(1):37–63.
   PubMedGoogle Scholar
• Zarenezhad E, Marzi M. Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Med Chem Res. 2022;1–12. DOI:https://doi.org/10.1007/s00044-021-02841-3
   Google Scholar
• Mrukowicz J, Rochwerg B, Jaeschke R. Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients? Pol Arch Intern Med. 2022;132(1). DOI:https://doi.org/10.20452/pamw.16183
   PubMedGoogle Scholar
• Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;6:199–207.
   Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.
   PubMed Web of Science ®Google Scholar
• Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant. 2022. https://doi.org/10.1111/ajt.16955.
   Google Scholar
• Younis NK, Zareef RO, Fakhri G, et al. COVID-19: potential therapeutics for pediatric patients. Pharmacol Rep. 2021;73(6):1520–1538.
   PubMedGoogle Scholar
• Yavuz S, Çelikyurt FI K, Yıldız N. Antiviral treatment of COVID-19: an update. Turk J Med Sci. 2021;51:1781–1790.
   PubMedGoogle Scholar
• Gottlieb RL, Juneja K, Hill JA. Outpatient remdesivir to prevent progression to severe covid-19. Reply. N Engl J Med. 2022;386(11):1094.
   PubMed Web of Science ®Google Scholar
• Kunal S, Sakthivel P, Malhotra N, et al. Newer oral antivirals for COVID-19: are they the real game changer? Heart Lung. 2022;52:200–203.
   PubMedGoogle Scholar
• Kovacech B, Fialova L, Filipcik P, et al. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine. 2022;76:103818.
   PubMed Web of Science ®Google Scholar
• Dawood AA. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Pathog. 2022;164:105400.
   PubMedGoogle Scholar
• Buchman TG, Draghia-Akli R, Adam SJ, et al. Accelerating coronavirus disease 2019 therapeutic interventions and vaccines-selecting compounds for clinical evaluation in coronavirus disease 2019 clinical trials. Crit Care Med. 2021;49(11):1963–1973.
   PubMed Web of Science ®Google Scholar
• Lee TC, Vigod S, Bortolussi-Courval É, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Network Open. 2022;5(4):e226269.
   PubMedGoogle Scholar
• Bonnet U, Juckel G. COVID-19 outcomes: does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-a scoping review. J Clin Psychopharmacol. 2022;42:284–292.
   PubMedGoogle Scholar
• Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with covid-19. N Engl J Med. 2022;386:1721–1731.
   PubMedGoogle Scholar